Bendamustine Produces Durable Responses With an Acceptable Safety Profile in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology,Hematology
Reference21 articles.
1. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
2. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology study;Herold;J Clin Oncol,2007
3. A phase III study of rituximab plus CVP versus CVP alone in patients with previously untreated advanced follicular lymphoma: updated results with 53 months’ median follow-up and analysis of outcomes according to baseline prognostic factors;Marcus;J Clin Oncol,2008
4. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma;Witzig;J Clin Oncol,2002
5. Efficacy and safety of tositumomab and iodine-131 toxitumomab (Bexxar) in B-cell lymphoma progressive after rituximab;Horning;J Clin Oncol,2005
Cited by 51 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Bendamustine impairs humoral but not cellular immunity to SARS-CoV-2 vaccination in rituximab-treated B-cell lymphoma–affected patients;Frontiers in Immunology;2023-12-01
2. Integrative approach to diagnosis and subsequent successful therapy of refractory follicular lymphoma using obinutuzumab in combination with bendamustine. Clinical observation;MD-Onco;2023-05-22
3. Bendamustine: a review of pharmacology, clinical use and immunological effects (Review);Oncology Reports;2022-05-03
4. Bendamustine and pneumocystis pneumonia: A systematic review;Health Science Reports;2022-04-26
5. Management of follicular lymphoma at first relapse;Canadian Hematology Today;2022-03-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3